Dermatology
Latest News
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
The co-primary endpoints were change in IGA and EASI scores at 16 weeks, and both improved rapidly, showing statistical significance relative to...
Latest News
Topical delgocitinib shows promise for chronic hand eczema, pivotal trial shows
Delgocitinib is an investigational topical pan-JAK inhibitor that inhibits activation of the JAK-STAT pathway.
Latest News
Air pollution may be causing eczema
There are now more than three times as many eczema cases as there were in the 1970s, and it now affects as many as 20% of children and 10% of...
News from the FDA/CDC
Cases of potentially deadly fungus jump 200%: CDC
People in hospitals and nursing homes are at a heightened risk because they might have weakened immune systems or be using invasive medical...
Latest News
CSU in children: Study identifies biomarkers associated with responses to different treatments
“Our study furthers our current understanding of the role of different biomarkers in treatment response.”
Conference Coverage
Lanolin gets nod for Allergen of the Year
Controversy continues over lanolin allergenicity; some patients with positive patch tests can tolerate lanolin ingredients.
Latest News
Study finds quality of topical steroid withdrawal videos on YouTube subpar
“We were disheartened that patient testimonial videos had the poorest quality and reliability of the information sources,” Erika McCormick said....
Latest News
Lebrikizumab monotherapy for AD found safe, effective during induction
Latest News
Spinosad: New kid on the block for treating scabies
The formulation “drives the active compound to the stratum corneum, where mites live and breed,” Dr. Anthony J. Mancini said.
Pediatric Dermatology Consult
A 9-year-old male presents with multiple thick scaly plaques on scalp, ears, and trunk
A nine-year-old boy presents with thick, scaly plaques on scalp, ears, and trunk.
Latest News
FDA to review dupilumab for treating chronic spontaneous urticaria
Dupilumab enters the approval process for adolescents and adults with uncontrolled CSU.